This is an urgent appeal for stem cell donors, for a Dad who was diagnosed in July 2018 with a high-risk form of MDS, Myelodysplastic Syndromes, a rare form of […]

1. SUB-TYPE OF MDS: Patients who have previously received a hypomethylating agent (eg. Azacitidine, Decitabine)
2. SEVERITY OF MDS: Intermediate-2 or High risk
3. NAME OF DRUG: Durvalumab, Tremelimumab, Azacitidine
Read full story

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? In this article David Steensma, MD FACP at the Dana-Farber Cancer Institute and […]

By Raqeebah Agberemi. Myelodysplastic Syndromes (MDS) are a wide range of disorders which affect the functionality of the bone marrow. Thus, blood cells such as red blood cells, white blood cells […]

On Thursday 22nd of November MDS UK was represented at a bone marrow donor drive at RAF Coningsby alongside the bone marrow donor charity, DKMS. The event was prompted by […]

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Print this article In this article Dr Timothy Chevassut, Consultant Haematologist at the […]

Research FOR PatientsFor an informed and empowered opinionand an improved consultationHave you made your clinical paper accessible yet? By Prof. David Bowen In order to develop new drugs to treat […]

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Print this article In 2012, MDS UK Patient Support Group started a research […]